Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. NVCR

Market Cap: $1.68B

NL

Novocure Ltd

NVCR
NASDAQUSD
Purchase NVCR
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

–
–(–)

Open

$17.00

Prev. Close

$14.68

High

$17.75

Low

$17.00

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

CEOFrank Leonard
SectorHealthcare
IndustryMedical - Devices

Recently from Cashu

Novocure Ltd Faces Mixed Results Ahead

Novocure Ltd Faces Mixed Results Ahead

The journey of Novocure Ltd is marked by significant achievements in the cancer treatment domain, particularly with its innovative TTFields technology. The recent news of the Phase 3 TRIDENT study, wh…

Cashu Finance·4 months ago
NovoCure's TRIDENT Study Shows No Survival Benefit for TTFields in Glioblastoma Treatment

NovoCure's TRIDENT Study Shows No Survival Benefit for TTFields in Glioblastoma Treatment

In a significant development for NovoCure Ltd. (Ticker: NVCR), the company recently reports topline results from its Phase 3 TRIDENT study, assessing the effectiveness of Tumor Treating Fields (TTFiel…

Cashu Finance·4 months ago
NovoCure Appoints Frank Leonard to Board Amid Strategic Shift in Governance and Market Challenges

NovoCure Appoints Frank Leonard to Board Amid Strategic Shift in Governance and Market Challenges

NovoCure (Ticker: NVCR) introduces a pivotal leadership change within its governance structure with the appointment of Frank Leonard to its board of directors. This decision follows a recent sharehold…

Cashu Finance·4 months ago

NovoCure Achieves 74.4% Disease Control Rate, Signaling Breakthrough in Cancer Treatment

NovoCure Shows Strong Progress in Disease Control Rates NovoCure is making notable advancements in its research and development efforts, as evidenced by a recent announcement detailing a disease contr…

Cashu Finance·7 months ago
Employees1.6K
IPO DateOct 2, 2015
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
AddressNeuhofstrasse 21
City / State / ZIPBaar, 6340
CountrySwitzerland
Phone44 15 3475 6700
Websitehttps://www.novocure.com